TY - JOUR
T1 - NCCTG study N9741
T2 - Leveraging learning from an NCI cooperative group phase III trial
AU - Goldberg, Richard M.
AU - Sargent, Daniel J.
AU - Morton, Roscoe F.
AU - Green, Erin
AU - Sanoff, Hanna K.
AU - McLeod, Howard
AU - Buckner, Jan
PY - 2009
Y1 - 2009
N2 - N9741 is a clinical trial in patients with metastatic colorectal cancer that was originally written in 1997 and completed patient accrual in 2004. One thousand seven hundred thirty-one patients were enrolled in the study. During the conduct of the trial, N9741 was repeatedly modified to adapt to toxicity findings, to add evaluation of oxaliplatin to what was originally a trial examining various schedules of irinotecan-based therapy, and to ask evolving questions. The trial led to a new U.S. Food and Drug Administration indication for 5-fluorouracil, leucovorin, and oxaliplatin as indicated for the treatment of previously untreated patients with metastatic colorectal cancer and helped to change the standard of care for the disease in the U.S. and worldwide. The data from the trial have been used to study multiple regimens, pharmacogenetics, and quality of life issues, to correlate plasma protein levels with outcomes, to inform trial methodology, and to perform economic analyses. To date nearly 30 papers and an even larger number of abstracts have been based upon data arising from the study. The history of the trial and the major findings are summarized in this review.
AB - N9741 is a clinical trial in patients with metastatic colorectal cancer that was originally written in 1997 and completed patient accrual in 2004. One thousand seven hundred thirty-one patients were enrolled in the study. During the conduct of the trial, N9741 was repeatedly modified to adapt to toxicity findings, to add evaluation of oxaliplatin to what was originally a trial examining various schedules of irinotecan-based therapy, and to ask evolving questions. The trial led to a new U.S. Food and Drug Administration indication for 5-fluorouracil, leucovorin, and oxaliplatin as indicated for the treatment of previously untreated patients with metastatic colorectal cancer and helped to change the standard of care for the disease in the U.S. and worldwide. The data from the trial have been used to study multiple regimens, pharmacogenetics, and quality of life issues, to correlate plasma protein levels with outcomes, to inform trial methodology, and to perform economic analyses. To date nearly 30 papers and an even larger number of abstracts have been based upon data arising from the study. The history of the trial and the major findings are summarized in this review.
KW - Clinical trial phase III
KW - Colorectal cancer meta-analysis
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=73349093435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73349093435&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2009-0175
DO - 10.1634/theoncologist.2009-0175
M3 - Review article
C2 - 19828593
AN - SCOPUS:73349093435
SN - 1083-7159
VL - 14
SP - 970
EP - 978
JO - Oncologist
JF - Oncologist
IS - 10
ER -